Nov. 7, 2014, 9:14 AM
- Gainers: MITK +29%. RMTI +27%. RPRX +24%. SHLD +22%. CNET +15%. NETE +11%. PGNX +10%. ZNGA +9%. APT +9%. KING +9%. KING +9%. KGC +8%. TKMR +7%. AGIO +7%. BEBE +5%.
- Losers: SLXP -35%. MDRX -20%. CTIC -19%. ICPT -19%. UBNT -17%. ANF -13%. ANET -11%. ORBC -10%. AVNR -7%. FSLR -7%. PLNR -6%. NDLS -6%. RIG -5%. DVA -5%. NADL -5%.
Feb. 12, 2014, 1:29 PM
- DaVita (DVA +5.5%) hits a new all-time high after cruising past earnings estimates last night and upping 2014 operating income guidance to $1.725B-$1.86B from $1.675B-$1.85B. Consolidated operating cash flow is expected at $1.45B-$1.55B.
- “[This year's] operating income guidance was increased on an improved dialysis outlook, and we suspect that will not be the last time,” says Feltl's Matt Weight, though warning upcoming Medicare Advantage rate projections from the Centers for Medicare and Medicaid - due next week - could dampen share growth.
- DaVita's dialysis centers are taking market share, says William Blair's Margaret Kaczor, noting the number of patients grew 5.2% in Q4, ahead of 4.7% projected, and faster than organic market growth of 4%.
Feb. 12, 2014, 9:10 AM
Feb. 11, 2014, 5:40 PM
Jan. 6, 2014, 2:09 PM
- McKesson (MCK -0.1%) upgraded to Strong Buy from Outperform at Raymond James.
- DaVita (DVA +0.4%) upgraded to Outperform from Market Perform at Raymond James.
- Idenix Pharmaceuticals (IDIX -0.3%) upgraded to Buy from Neutral at UBS.
- Abbott Labs (ABT +1.5%) upgraded to Overweight from Equalweight at Morgan Stanley.
- Medtronic (MDT +2%) upgraded to Overweight from Neutral at JPMorgan. Price target is $69.
- Vertex Pharmaceuticals (VRTX +2.5%) upgraded to Buy from Neutral at UBS.
- Ocera Therapeutics (OCRX +2.7%) upgraded to Outperform from Market Perform at BMO.
- Boston Scientific (BSX +3.2%) upgraded to Overweight from Equalweight at Morgan Stanley.
- Exelixis (EXEL +4.6%) upgraded to Overweight from Neutral at Piper.
- St. Jude Medical (STJ +3.8%) upgraded to Overweight from Equalweight at Morgan Stanley.
Dec. 18, 2013, 10:03 AM
- Susquehanna starts Acadia Healthcare (ACHC +1.3%) at Positive. Price target is $56.
- Jefferies starts Mirati Therapeutics (MRTX +1.9%) at Buy. Price target is $36.
- KeyBanc initiates DaVita (DVA +1.5%) at Buy. Price target is $73.
- JMP starts Illumina (ILMN +1.1%) at Market Outperform. Price target is $125.
- KeyBanc starts IPC (IPCM -0.6%) at Hold.
- KeyBanc starts Envision Healthcare (EVHC +1.6%) at Buy. Price target is $40.
- JMP starts Quest Diagnostics (DGX -0.9%) at Market Perform.
- KeyBanc starts Team Health (TMH -0.8%) at Hold.
- JMP starts Lab Corp (LH -0.3%) at Market Perform.
- Goldman upgrades HCA Holdings (HCA +1.6%) to Conviction Buy.
- MKM downgrades Targacept (TRGT -3.1%) to Neutral from Buy.
Nov. 25, 2013, 10:07 AM
- "The good news is that Medicare rates will not be decreased next year, when most thought rates would be down," DaVita HealthCare's (DVA +6.6%) group VP LeAnne Zumwalt says, reacting to the final CMS Medicare ESRD rule for 2014.
- "The bad news is ... that Medicare dialysis rates will be flat in 2014 and 2015 in an environment of increasing expenses," Zumwalt adds.
- In light of the rule, DVA provides the following guidance for FY14: Enterprise operating income, $1.675-1.85B; operating income for dialysis services and related ancillary businesses, $1.425 to $1.54B; operating income for HCP, $250 to $310M. (PR)
Nov. 25, 2013, 7:26 AM
- Shares in Fresenius Medical Care (FMS) are +8.3% and those of DaVita HealthCare Partners (DVA) +6.1% after the Centers for Medicare & Medicaid Services scrapped a proposed 9.4% cut in reimbursement rates for dialysis treatment for patients with end-stage renal disease.
- Instead, payments for 2014 and 2015 they will remain flat.
Nov. 22, 2013, 5:36 PM
Aug. 6, 2013, 5:12 PM
- DaVita HealthCare Partners (DVA) rises 1.21% AH after posting Q2 results.
- Total U.S. dialysis treatments for Q2 were 5,867,973 — treatments rose 7.6% Y/Y on a per day basis.
- FY13 consolidated operating income guidance is raised to $1.83-1.93B. The company also lifts the bottom end of its full year consolidated operating cash flow outlook to $1.4B from $1.35B. (PR)
Jul. 16, 2013, 10:02 AM
DaVita (DVA -1.8%) slips as Goldman cuts the shares to Sell from Neutral (price target $110). A "a meaningful contribution from future growth drivers [is] several years away," analyst Matthew Borsch says, adding that "growth in the physician integrated care model has been harder to achieve than expected." Like Deutsche, Goldman thinks 2014 estimates may be difficult to hit and with the shares back to pre-CMS rate announcement levels, it may be a good time to take some off the table.| Jul. 16, 2013, 10:02 AM
Jul. 2, 2013, 1:00 PM
Deutsche Bank comments on the impact to DaVita (DVA -4.9%) of CMS' 2014 Medicare ESRD proposed rule - which reduces dialysis rates by 9.4% - saying the figure is twice as high as expected. Deutsche doesn't plan to make any changes to DVA's model at present, as it expects CMS to make adjustments in a final rule, but the changes would have to improve significantly for for the firm to remain confident in 2014 estimates.| Jul. 2, 2013, 1:00 PM
Jul. 2, 2013, 9:12 AM
Jul. 1, 2013, 5:37 PM
DaVita HealthCare (DVA) slips in the post-session on reports the U.S. Medicare program plans to cut payments to dialysis centers by 9.4% next year, according to a proposal posted online Monday afternoon. Cuts are part of a budget balancing law passed last year. Fresenius Medical Care (FMS) also trades lower on the news. DVA -5.5%, FMS -1.5% AH.| Jul. 1, 2013, 5:37 PM
May 8, 2013, 10:58 AM
DaVita Health (DVA +10.2%) moves higher today on the back yesterday's Q1 earnings beat and some positive strategic developments outlined in its disclosure. Sales jumped 50% Y/Y, largely as a result of its acquisition of HealthCare Partners, but net income fell roughly 64% due to $300M in reserve charges to settle a federal investigation into a potential kickback scheme. Additionally, the company also disclosed an agreement with Berkshire Hathaway that will prevent it from engineering a takeover of the firm.| May 8, 2013, 10:58 AM
Feb. 15, 2013, 2:26 PMDaVita (DVA -1.5%) trades lower today on a downgrade to Neutral on relative valuation at Goldman Sachs. The firms notes that while its outlook for core dialysis remains solid, we expect slower growth with less upward momentum relative to its peers over the next 12-24 months." | Feb. 15, 2013, 2:26 PM | 2 Comments